$162 Million is the total value of VHCP Management III, LLC's 17 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 35.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc | $38,541,000 | -31.3% | 2,066,529 | 0.0% | 23.79% | -9.2% | |
| AXSM | Axsome Therapeutics Inc | $32,613,000 | -21.4% | 1,611,329 | 0.0% | 20.13% | +3.9% | |
| RARX | Ra Pharmaceuticals | $15,854,000 | -21.3% | 670,350 | 0.0% | 9.79% | +4.0% | |
| TXG | New | 10X Genomics Inc. | $15,120,000 | – | 300,000 | +100.0% | 9.33% | – |
| PTGX | Protagonist Therapeutics Inc | $12,879,000 | -0.8% | 1,072,348 | 0.0% | 7.95% | +31.1% | |
| LJPC | La Jolla Pharmaceuticals | $11,017,000 | -4.9% | 1,251,898 | 0.0% | 6.80% | +25.8% | |
| OBSV | Obseva SA | $9,661,000 | -26.3% | 1,159,789 | 0.0% | 5.96% | -2.6% | |
| BCRX | BioCryst Pharmaceuticals Inc | $7,759,000 | -24.4% | 2,708,207 | 0.0% | 4.79% | -0.0% | |
| KALV | Kalvista Pharmaceuticals | $7,399,000 | -47.6% | 637,884 | 0.0% | 4.57% | -30.8% | |
| MRNS | Buy | Marinus Pharmaceuticals Inc | $3,875,000 | -25.8% | 2,516,164 | +99.9% | 2.39% | -2.0% |
| TCDA | Sell | Tricida Inc | $2,480,000 | -78.3% | 80,348 | -72.3% | 1.53% | -71.3% |
| KNSA | Sell | Kiniksa Pharmaceuticals Ltd | $2,358,000 | -44.2% | 277,137 | -11.3% | 1.46% | -26.3% |
| BLPH | Bellerophon Therapeutics | $1,165,000 | -19.7% | 2,417,227 | 0.0% | 0.72% | +6.2% | |
| RDUS | New | Radius Health Inc | $596,000 | – | 23,131 | +100.0% | 0.37% | – |
| CNST | Constellation Pharmaceuticals | $431,000 | -47.4% | 66,667 | 0.0% | 0.27% | -30.4% | |
| PTI | Proteostasis Therapeutics Inc | $187,000 | -13.4% | 221,267 | 0.0% | 0.12% | +13.9% | |
| PRVL | New | Prevail Therapeutics Inc | $54,000 | – | 4,408 | +100.0% | 0.03% | – |
| GEMP | Exit | Gemphire Therapeutics | $0 | – | -798,066 | -100.0% | -0.30% | – |
| KDMN | Exit | Kadmon Holdings Inc. | $0 | – | -422,141 | -100.0% | -0.41% | – |
| ORTX | Exit | Orchard RX Ltd | $0 | – | -676,252 | -100.0% | -4.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
| Obseva SA | 6 | Q4 2019 | 15.8% |
| Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
| Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
| Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
| BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
| Tricida Inc | 5 | Q3 2019 | 15.0% |
| Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
| Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
| Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-22 |
| 4 | 2024-02-08 |
| 4 | 2024-02-01 |
| 4 | 2024-01-29 |
| 4 | 2024-01-24 |
| 4 | 2024-01-19 |
| 4 | 2024-01-16 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.